The relationship among iron status, ferritin, and folate levels, and the possible contribution of folate measurement in the prediction of iron response in hemodialysis patients, have not been assessed. In addition to serum ferritin and transferrin saturation (TSAT), serum and red blood cell (RBC) folate levels were evaluated as indices for intravenous iron therapy responsiveness in 60 hemodialysis patients. Patients were classified as iron responders or nonresponders depending on whether they exhibited a rise in hemoglobin above 1 g/dl after administration of 1 g of iron sucrose. An inverse relation between serum ferritin concentration and RBC folate levels was found in iron responders (n ‫؍‬ 26, r ‫؍‬ -0.62, p < 0.001) but not in nonresponders (n ‫؍‬ 34, r ‫؍‬ 0.07, p ‫؍‬ nonsignificant). Only serum and RBC folate levels could predict iron response in patients with ferritin levels above 150 g/l (n ‫؍‬ 25), with a sensitivity of 83.3% and a specificity of 94.7%. Our findings suggest that RBC folate concentration is inversely related with ferritin levels in iron-responsive but not in non-responsive hemodialysis patients. Serum and RBC folate concentration seems to predict response to iron administration better than serum ferritin or TSAT in patients with ferritin levels above 150 g/l; therefore, in these patients, it might be used to guide iron management.
Serum ferritin is a universally available and well-standardized measurement considered to be the most valuable laboratory test in the diagnosis of iron deficiency. 1 However, ferritin is an acute phase protein, and thus, serum concentrations may increase for reasons independent of iron status. In addition, in patients with end-stage renal disease (ESRD), the accelerated erythropoiesis resulting from the administration of recombinant human erythropoietin (rHuEPO) increases iron requirements and may result in functional iron deficiency. Fishbane et al. 2 report that a serum ferritin value below 150 g/l is optimal for the diagnosis of iron deficiency in patients on hemodialysis with a sensitivity of 71% and a specificity of 69%. In another study, Kalantar-Zadeh et al. 3 report a ferritin sensitivity of only 41% using a cutoff value of 200 g/l. Therefore, the use of ferritin as the sole index of iron deficiency in hemodialysis patients fails to detect this condition in a considerable number of patients with normal or high serum ferritin levels.
Ferritin represents the major iron-storage protein and its spherical shell is composed of 24 polypeptide subunits of at least two types: H (heavy) and L (light). We initiated our study based on experimental reports. Han et al. 4 reported that iron deficiency was accompanied by an increase in the proportion of H ferritin subunits in the brain cells of an animal model. Suh et al. 5 also found that, in a cell culture, H ferritin subunits catabolize folate suggesting that this could constitute a significant mechanism for in vivo regulation of folate concentration. Taken together, these findings give rise to the intriguing possibility that the co-occurrence of iron deficiency and increased ferritin levels, due to the relative predominance of H ferritin subunits, might result in accelerated folate turnover and thus decreased folate concentrations. Therefore, measurement of folate may be useful in revealing the underlying iron deficiency. However, the complex relation among iron status, ferritin, and folate levels has not been investigated.
At present, the only definitive way to diagnose functional iron deficiency is to assess the erythroid response to additional iron administration. 2 Functional iron deficiency is characterized by the presence of adequate iron stores as defined by conventional criteria (ferritin or transferrin saturation [TSAT]), but with the inability to sufficiently mobilize this iron to adequately support erythropoiesis. In an attempt to identify patients with functional iron deficiency we administered intravenous iron and assessed the hematologic response. We examined the relation between ferritin levels and folate concentration separately in iron-responsive and nonresponsive hemodialysis patients, and we tested the hypothesis that, among patients with normal to high ferritin concentrations, folate levels would be lower in iron responders than in nonresponders. In other words, our study aimed at assessing a possible application of measuring folate levels in the detection of those hemodialysis patients who, despite normal or high ferritin levels, require a more intensive iron supplementation. We also assessed the value of serum ferritin and TSAT for predicting response to intravenous iron in patients on chronic hemodialysis.
Materials and Methods
We conducted a cross-sectional study in patients with ESRD who were on outpatient hemodialysis three times per week, for 3.5-4 hours each session. The criteria for inclusion were: age older than 18 years, stable clinical condition for at least 3 months before enrollment, no hematologic disease other than anemia, unvarying rHuEPO maintenance dose for a period longer than 2 months, no transfusions or per os/parenteral iron administration for at least 2 months, administration of folic acid at an unchanged dose of 5 mg daily, and a vitamin B complex preparation on every dialysis session, for at least 2 months before enrollment, and TSAT below 50% and serum ferritin below 500 g/l. Subjects were excluded if, at the time of enrollment, they were found to have B 12 or folate deficiency, severe hyperparathyroidism (intact parathyroid hormone Ͼ 800 pg/ml) or aluminum intoxication (serum aluminum Ͼ 60 g/l). Subjects were also excluded if they were receiving drugs that might interfere with folate metabolism, such as phenytoin, methotrexate, trimethoprim, primidone, para-aminosalicylic acid, sulfasalazine, or oral contraceptives. All included patients were advised to follow a diet containing a folate content of 0.8 mg per day, for at least 1 month before their enrollment. Dietary intake of folate was assessed using the 24-hour dietary recall methodology.
The study protocol was approved by the Institutional Review Board of the "Papageorgiou" General Hospital. Written informed consent was obtained from each subject before enrollment in the study.
Baseline laboratory parameters, including complete blood count, serum ferritin, TSAT, serum and red blood cell (RBC) folate levels, vitamin B 12 concentration, C-reactive protein levels, aluminum concentration, and intact parathyroid hormone levels, were obtained before iron administration. Blood samples were collected from the arterial needle before hemodialysis. Eligible subjects were treated with intravenous iron sucrose at a total dose of 1 g, divided over 10 consecutive hemodialysis treatments. Complete blood count panels were repeated at 2, 3, 4, 5, and 6 weeks after the initiation of iron treatment. Subjects that exhibited an increase in hemoglobin concentration above 1 g/dl within 6 weeks were classified as iron responders and the rest as nonresponders. No alterations in rHuEPO dosage were made during the study period.
Serum ferritin was measured by a microparticle enzyme immunoassay technique (Abbott Laboratories, New York, NY). The TSAT was calculated using the formula: TSAT (%) ϭ serum iron (g/dl) ϫ 100 / total iron -binding capacity. The RBC and serum folate were measured using an ion capture technique (normal range: 225-577.1 ng/ml and 5.3-14.4 ng/ml, respectively) (Abbott Laboratories). According to this technique, negatively charged analyte complexes are formed through the binding reaction between folate and folate binding protein (FBP) affinity coupled to monoclonal antibodies, which are in turn covalently coupled to carboxymethylamylose. The negatively charged analyte complexes are then captured through electrostatic interaction with a positively charged glass fiber matrix. Folate is quantified by measuring the population of unoccupied FBP sites bound to the matrix using a conjugate of pteroic acid and alkaline phosphatase as the signal generating molecule and a substrate, 4-methylumbelliferyl phosphate.
Statistical Analysis
Continuous variables are shown as mean Ϯ standard deviation (SD). Student's t test or Pearson's chi-square test were used to examine the statistical significance of differences between iron-responsive and nonresponsive patients. Pearson correlation analysis was used to estimate correlations between iron status parameters. Receiver operating characteristic (ROC) curve analysis was performed by computing sensitivity and specificity associated with various cutoff values for TSAT, folate, and ferritin levels to identify the optimal value in terms of sensitivity and specificity, which can predict an increase in hemoglobin of more than 1 g/dl (10 g/l) within 6 weeks after the initiation of iron therapy. The positive and negative predictive values were also determined. All statistical analyses were based on two-tailed hypothesis tests, with a significance level of p Ͻ 0.05. Statistical analyses were conducted using the SPSS 10.0 statistical software for Windows (SPSS Inc., Chicago, IL).
Results
Sixty-one patients fulfilled the criteria for admission to the study and received 1 g intravenous iron sucrose according to the study protocol. No allergic reactions or intolerance during or after the infusion of iron sucrose were noted. During the follow-up period, one patient was transferred to another dialysis center and was excluded from the study. A total of 60 patients completed the study protocol. All patients were white, and 48 had urine output of less than 100 ml/day. Low-flux membranes were used for 54 patients (90%) and high-flux membranes for the remaining six. Dialyzers were not being reused. Fifty-one patients (85%) were receiving rHuEPO one to three times per week, aiming at hemoglobin values of 11 to 12 g/dl. During the course of the study, none of the patients required hospitalization for systemic infection, clinically significant bleeding, or any kind of surgery.
Twenty-six patients (43.3%) responded to intravenous iron treatment, increasing their hemoglobin level by 1 g/dl or more within 6 weeks (mean increase: 1.73 Ϯ 0.85 g/dl) and 34 patients (56.7%) did not respond to iron treatment (mean increase in hemoglobin: 0.14 Ϯ 0.53 g/dl). In the iron-responders group, 21 patients (81%) were receiving rHuEPO therapy (mean dose: 107 U/kg per week), as opposed to 30 (88%) in the nonresponders group (mean dose: 113 U/kg per week) (p ϭ nonsignificant). In the iron-responders group, 65.4% (17 of 26) of patients had ferritin values less than 100 g/l, 42.3% (n ϭ 11) had TSAT below 20%, and 34.6% (n ϭ 9) had both. The same figures for the nonresponders group were 17.6% (6 of 34), 5.9% (n ϭ 2), and 2.9% (n ϭ 1), respectively (for all comparisons p Ͻ 0.005). Table 1 compares the two groups in terms of demographics, erythropoietin administration, and laboratory measurements. With the exception of lower serum ferritin, TSAT, and serum folate levels in the iron-responders group, the two groups did not differ significantly in any laboratory measurements at baseline. In addition, a nonsignificant trend toward lower RBC folate values was noted in the iron-responders group. Serum ferritin level below 60 g/l was the best single indicator for iron responsiveness, with a sensitivity of 61.5%, specificity of 91.2%, positive predictive value of 84.2%, and negative predictive value of 75.6%.
Serum and RBC folate levels were significantly correlated (r ϭ 0.50, p Ͻ 0.001) in the whole study population. Ferritin was positively correlated with TSAT (r ϭ 0.50, p Ͻ 0.001) and inversely related with RBC folate levels (r ϭ -0.26, p Ͻ 0.048). No significant correlations were noted between hemoglobin concentrations or any of the iron indices and iPTH or serum aluminum levels. In addition, no correlation was noticed between serum and RBC folate levels and membrane type (lowflux vs. high-flux) or urine output.
Red blood cell folate was inversely related to ferritin in the iron responders group (r ϭ -0.62, p ϭ 0.001) but not in the nonresponders group (r ϭ 0.07, p ϭ nonsignificant) (Figure 1) . Serum folate was also inversely related to ferritin in the iron responders group, albeit to a marginally nonsignificant degree (r ϭ -0.35, p ϭ 0.084). Table 2 summarizes the data of Table 1 for patients with ferritin values above 150 g/l (n ϭ 25). Those who were classified as iron responders (n ϭ 6) had significantly lower serum and RBC folate levels (15.0 Ϯ 5.6 ng/ml and 695 Ϯ 329 ng/ml, respectively) compared with those classified as nonresponders (33.1 Ϯ 15.1 ng/ml and 1184 Ϯ 175 ng/ml, respectively) (p Ͻ 0.001 and p ϭ 0.013, respectively); no significant differences in other laboratory measurements were present. This indicates that serum or RBC folate levels may be capable of detecting functional iron deficiency in patients with serum ferritin above 150 g/l. Based on ROC curve analyses, a serum folate or an RBC folate concentration below 17.3 ng/ml and 915 ng/ml was the optimal cutoff to predict a hemoglobin response after initiation of iron therapy, with sensitivity of 83.3%, specificity of 94.7%, positive predictive value of 83.3%, and negative predictive value of 94.7%. Both sensitivity and specificity of folate exhibited a rising trend with increasing ferritin cutoff values for discriminating between lower-and higher-ferritin patients. For example, in groups with ferritin levels above 100, 130, or 150, sensitivity was 78%, 71%, and 83% respectively, and specificity was 71%, 95%, and 95%, respectively. This however occurred at the expense of attributing patients that responded to iron treatment to the lower-ferritin group. These patients were being classified as nonresponders on the basis of their ferritin levels alone. A ferritin level of 150 g/l was the lowest value in which both sensitivity and specificity of serum and RBC folate levels rose above 80%. Table 3 summarizes the same data for patients with ferritin values Յ 150 g/l (n ϭ 35). Both serum ferritin concentration and TSAT were significantly lower in iron-responsive (n ϭ 20) compared to nonresponsive patients (42 Ϯ 42 g/l, vs. 91 Ϯ 44 g/l, p ϭ 0.002 and 21 Ϯ 10% vs. 28 Ϯ 10%, p ϭ 0.039, respectively). At this level of ferritin values, serum and RBC folate levels did not differ between iron responders and nonresponders. Serum ferritin levels below 60 g/l or TSAT levels below 24.7% were the optimal cutoff values for detecting iron responsiveness, with 80% and 70% sensitivity, 80% and 60% specificity, 84.2% and 70% positive predictive value, and 75% and 60% negative predictive value, respectively.
Compared with the use of serum ferritin as the sole iron deficiency index, the additional measurement of either serum or RBC folate in patients with ferritin levels above 150 g/l significantly improved detection of iron responsiveness in hemodialysis patients, raising sensitivity from 61.5% to 80.8% with a negligible reduction in specificity, from 91.2% to 88.2%.
Discussion
Iron deficiency occurs in the majority of patients undergoing hemodialysis and is the most common cause of rHuEPO treatment failure. Serum ferritin and TSAT are the most widely used tests for assessing iron status in these patients. Actually these are the only tests recommended by the NKF/DOQI Guidelines, 6 even though inflammatory states and uremia itself limit their reliability. Several additional diagnostic tests, including zinc protoporphyrin concentration, 7 serum transferrin receptors, 8 and particularly the percentage of hypochromic red cells 9 and the reticulocyte hemoglobin concentration, 10 have proven to be of value in detecting iron deficiency in hemodialysis patients, but require specialized equipment and are not widely available.
It has been suggested that ferritins enriched in L subunits seem to serve long-term iron storage needs whereas ferritins with a predominance of H subunits may be more active in iron metabolism. 11 Iron overload in both animal models and cell cultures decreases H/L ferritin subunit ratio, the synthesis of L subunits being preferentially stimulated over H subunit synthesis. 12, 13 In contrast, H subunits increase significantly in iron deficiency, with H/L subunit ratio increasing from 45:1 in controls to over 60:1 in iron-deficient animals. 4 In vivo folate catabolism has been assumed to include random, nonenzymatic, oxidative degradation of labile cofactors. 14 However, in a recent study by Suh et al., 5 a folate-catabolizing enzyme, regulating intracellular folate concentration, has been isolated and purified from rat liver and was found to be identical to ferritin. Overexpression of rat H ferritin subunits in Chinese hamster ovary cells increased folate turnover proportionally. Likewise, increased rates of H over L ferritin subunit synthesis have been detected in various conditions, like pregnancy 15 and malignancy, 16 where increased rates of folate catabolism have also been observed. 17, 18 It is certainly difficult to extrapolate conclusions derived from experimental findings to clinical studies. However, these basic science findings have fueled our interest in conducting a clinical trial. Our study aimed first at identifying a possible relationship between serum ferritin and folate levels in ironresponsive and nonresponsive hemodialysis patients, and second at evaluating whether folate levels can be used for detecting iron responsiveness. To the best of our knowledge, this is the first study evaluating the relation among iron status, ferritin, and folate levels in humans, and in hemodialysis patients in particular. Our results suggest the presence of an inverse relationship between folate and serum ferritin levels in iron-responsive, but not in non-iron-responsive hemodialysis patients.
In our study, both measurements of serum and of RBC folate concentration, in patients with ferritin levels above 150 g/l (n ϭ 25), shared the same high sensitivity (83.3%) and specificity (94.7%) for the prediction of iron responsiveness. In principle, that means that among patients with ferritin values above 150 g/l, which due to their high ferritin are not considered iron deficient, 83.3% of those with serum and RBC folate levels below 17.3 ng/ml and 915 ng/ml respectively, will respond to iron administration. These sensitivity and specificity values have been calculated in a group of 25 patients, 6 of whom were iron responders and 19 were nonresponders. These results are also strengthened by the presence of a significant negative correlation between ferritin and RBC folate concentration only in iron-responsive patients enrolled in our study (Figure 1) . The validity of sensitivity and specificity indices in the 25 patients with serum ferritin levels above 150 g/l is of course proportionate to the number of participating patients. Unfortunately, past studies on the sensitivity and specificity indices of iron deficiency in hemodialysis patients were not able to determine the most accurate tests that identify patients with absolute or functional iron deficiency, and several of them include analyses based on similar population sizes to our own study. 3, 19 However, in patients with ferritin concentrations Յ 150 g/l, ferritin was a better iron-responsiveness index than both TSAT, a finding consistent with other studies, 20 and folate levels. The measurement of ferritin in all patients, combined with measurement of folate in those patients with serum ferritin concentration above 150 g/l, significantly improves the prediction rate of iron-responsiveness compared to the use of ferritin as the sole index, raising sensitivity from 61.5% to 80.8%, with a minimal decline in specificity, from 91.2% to 88.2%. Serum and RBC folate levels were not reliable ironresponse indices in patients with ferritin concentration Յ 150 g/l. This might be attributed to the small quantity of H subunits in patients with low ferritin concentrations, which would be insufficient to exert a significant additional effect on nonenzymatic folate catabolism.
In iron responders, ferritin exhibited a poorer correlation with serum folate as opposed to that with RBC folate concentration (r ϭ -0.35, p ϭ 0.084 vs. r ϭ -0.62, p ϭ 0.001, respectively). Folate is concentrated in greater amounts in erythrocytes and RBC folate levels are likely to reflect longterm intake more accurately than serum levels, and thus are considered a more reliable indicator of folate stores. 21 However, this discrepancy between RBC and serum folate levels, reflected in their correlation coefficient (r ϭ 0.50, p Ͻ 0.001), does not limit either one's ability to predict iron responsiveness in patients with high ferritin concentrations, because both measurements share the same high sensitivity and specificity indices.
Patients in our study received a folate supplement at a constant daily dose of 5 mg. We therefore calculated cutoff values for serum and RBC folate based on this specific intake level. Had no or a different dose of supplemental folate been given, cutoff values would be expected to be different. A more practically applicable protocol to assess possible functional iron deficiency in those patients, probably by measuring folate concentration after an acute administration of a fixed folate dose, should be evaluated in the future. The dietary intake of folate in our patients was lower than 1 mg daily. The supplemental administration of 5 mg of folate daily would attenuate any possible effect of variation in dietary intake on the difference in folate concentration between iron-responsive and nonresponsive patients.
In conclusion, our findings identify for the first time a relationship among folate concentration, ferritin levels, and iron status in ESRD patients. The RBC folate concentration is inversely related with ferritin levels in iron-responsive but not in nonresponsive hemodialysis patients. In patients with serum ferritin levels above 150 g/l, a serum folate or an RBC folate concentration below 17.3 ng/ml and 915 ng/ml was the optimal cutoff to predict a hemoglobin response after initiation of iron therapy, with sensitivity of 83.3% and specificity of 94.7%. Additional studies in larger groups of patients will determine whether the use of serum or RBC folate will lead to a better anticipation of response to supplemental iron in ESRD patients with high or upper-normal ferritin levels.
